CAH vs HSIC
Cardinal Health and Henry Schein, both Healthcare
Cardinal Health is the larger company at $55B against $9.4B. Over the past year CAH returned +60% against +24% for HSIC.
| Figure | CAH | HSIC |
|---|---|---|
| Last close | $238 | $84.26 |
| Market cap | $55B | $9.4B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | n/a | 24.6 |
| Dividend yield | 0.9% | n/a |
| 1-year return | +60% | +24% |
| 5-year return | +408% | +7.4% |
| RyuScoresector-relative, 1–10 | 61/100 | 61/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Cardinal Health
Revenue of $125B in H2 2026, net income $797M. Its largest reported line is Pharmaceutical And Specialty Solutions, 94% of the disclosed total.
Henry Schein
Revenue of $3.5B in Q2 2026, net income $94M. Its largest reported line is Global Distribution And Value Added Services, 69% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.